Table 122Evidence summary table: fluphenazine versus olanzapine – specific adverse events

OutcomeStudiesParticipantsEffect EstimateI2Less with
BMI and weight
Weight gain891600.09 (0.01, 1.57)NEND
CNS
Stupor891603.00 (0.13, 70.83)NEND
EPS
Akathisia891600.33 (0.10, 1.11)NEND
Dyskinesia891600.25 (0.03, 2.11)NEND
Dyskinetic symptoms891602.00 (0.19, 20.90)NEND
Hypertonia891600.33 (0.04, 3.03)NEND
Parkinsonism891601.20 (0.41, 3.51)NEND
Tremor891601.50 (0.27, 8.34)NEND
Sleep
Insomnia891600.08 (0.00, 1.31)NEND

AE = adverse event; BMI = body mass index; CNS = central nervous system; EPS = extrapyramidal symptoms/syndrome; I2 = I–squared; ND = no difference; NE = not estimable

From: Appendix N, Summary Tables of Adverse Events

Cover of First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 63.
Abou-Setta AM, Mousavi SS, Spooner C, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.